



AFRL-RX-TY-TP-2009-4565

PREPRINT

**ANALYSIS OF CHEMICAL OFF-GASSING FROM FILTERING
FACEPIECE RESPIRATORS AFTER DECONTAMINATION**

**W. Bruce Salter, Kimberly Kinney, William H. Wallace, April E. Lumley,
Brian K. Heimbuch**
Applied Research Associates
Tyndall Air Force Base, FL 32403

Joseph D. Wander
Air Force Research Laboratory

AUGUST 2009

**Distribution Statement A:
Approved for public release; distribution unlimited.**

**This document was submitted to Springer for publication in the Journal of
Material Science.**

**This material is declared a work of the U.S. Government and is not subject to
copyright protection in the United States.**

**AIRBASE TECHNOLOGIES DIVISION
MATERIALS AND MANUFACTURING DIRECTORATE
AIR FORCE RESEARCH LABORATORY
AIR FORCE MATERIEL COMMAND
139 BARNES DRIVE, SUITE 2
TYNDALL AIR FORCE BASE, FL 32403-5323**

REPORT DOCUMENTATION PAGE

*Form Approved
OMB No. 0704-0188*

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) 31-AUG-2009		2. REPORT TYPE Journal Article PREPRINT		3. DATES COVERED (From - To) 01-FEB-2008 -- 01-AUG-2009	
4. TITLE AND SUBTITLE Analysis of Chemical Off-Gassing from Filtering Facepiece Respirators after Decontamination (PREPRINT)				5a. CONTRACT NUMBER FA4819-07-D-0001	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER 99999F	
6. AUTHOR(S) *Salter, W. Bruce; *Kinney, Kimberly; *Wallace, William H.; *Lumley, April E.; *Heimbuch, Brian K.; **Wander, Joseph D.				5d. PROJECT NUMBER DODT	
				5e. TASK NUMBER L0	
				5f. WORK UNIT NUMBER Q220L7AD	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) *Applied Research Associates P.O. Box 40128 Tyndall Air Force Base, FL 32403				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) **Air Force Research Laboratory Materials and Manufacturing Directorate Airbase Technologies Division 139 Barnes Drive, Suite 2 Tyndall Air Force Base, FL 32403-5323				10. SPONSOR/MONITOR'S ACRONYM(S) AFRL/RXQL	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S) AFRL-RX-TY-TP-2009-4565	
12. DISTRIBUTION/AVAILABILITY STATEMENT Distribution Statement A: Approved for public release; distribution unlimited.					
13. SUPPLEMENTARY NOTES Ref AFRL/RXQ Public Affairs Case # 09-139. Submitted to Springer for publication in the Journal of Material Science. Document contains color images.					
14. ABSTRACT <p>A major concern among healthcare experts is a shortage of supplies during a pandemic. An item of particular interest is the N95 filtering facepiece respirator (FFR), which is responsible for protecting individuals from infectious aerosols. Most experts agree there will be a shortage of N95 FFRs if a severe pandemic occurs and one option for mitigating an FFR shortage is to decontaminate and reuse the devices. Many parameters must be studied to verify the effectiveness of this strategy: biocidal efficacy of the decontamination treatment, filtration performance, pressure drop, fit, and toxicity to the end user post treatment. The focus of this research effort was to measure chemical off-gassing of six types of FFRs following decontamination. Our data indicate that for disinfectants, such as hydrogen peroxide and bleach, the amount of residual decontaminants is below the Permissible Exposure Limit (PEL). Toxic by-products were also evaluated, and they were detected for ethylene oxide treatment of FFR rubber straps. These data are encouraging and may contribute to the evolution of effective strategies for decontamination and reuse of FFRs.</p>					
15. SUBJECT TERMS pandemic, respirator, infectious, aerosols, H1N1, decontaminate					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 24	19a. NAME OF RESPONSIBLE PERSON Joseph D. Wander
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (Include area code)

Reset

1 **Analysis of Chemical Off-Gassing from Filtering Facepiece**
2 **Respirators after Decontamination**

3 **Salter¹, W. Bruce, K. Kinney¹, W.H. Wallace¹, A.E. Lumley¹, B.K. Heimbuch¹**
4 **and J.D. Wander²**

5 **¹Applied Research Associates, Inc., Tyndall Air Force Base, FL 32403**

6 **²Air Force Research Laboratory, Tyndall Air Force Base, FL 32403**

7 **Abstract**

8 A major concern among healthcare experts is a shortage of supplies during a pandemic. An item of
9 particular interest is the N95 filtering facepiece respirator (FFR), which is responsible for protecting
10 individuals from infectious aerosols. Most experts agree there will be a shortage of N95 FFRs if a severe
11 pandemic occurs and one option for mitigating an FFR shortage is to decontaminate and reuse the
12 devices. Many parameters must be studied to verify the effectiveness of this strategy: biocidal efficacy
13 of the decontamination treatment, filtration performance, pressure drop, fit, and toxicity to the end user
14 post treatment. The focus of this research effort was to measure chemical off-gassing of six types of
15 FFRs following decontamination. Our data indicate that for disinfectants, such as hydrogen peroxide and
16 bleach, the amount of residual decontaminants is below the Permissible Exposure Limit (PEL). Toxic by-
17 products were also evaluated, and they were detected for ethylene oxide treatment of FFR rubber straps.
18 These data are encouraging and may contribute to the evolution of effective strategies for
19 decontamination and reuse of FFRs.

20
21 **Introduction**

22 Pandemic influenza outbreaks historically occur every 40 to 50 years. The last pandemic was the Hong
23 Kong Flu in 1968 so the next cycle could be realized during the autumn flu season of 2009 if the spring
24 outbreak of H1N1 “Swine Flu” reemerges in the more-virulent episode that health experts fear. A
25 primary barrier used to protect healthcare workers and the general public from airborne infections is the
26 National Institute for Occupational Safety and Health (NIOSH)-approved filtering facepiece respirator
27 (N95 FFR; note – many types of FFRs are available. The focus of this report is the N95 FFRs. All
28 further references to FFRs in this manuscript specify N95 FFRs). The FFR is rated to capture $\geq 95\%$ of
29 airborne particles and has been proven to remove infectious microorganisms from the air stream.⁽¹⁻⁶⁾ A
30 looming concern among healthcare providers is the anticipated outbreak of an influenza pandemic. These
31 fears were aggravated in the spring of 2009 with the onset of an H1N1 outbreak.^(7,8) On June 11, 2009,
32 the World Health Organization (WHO) raised the pandemic alert level to six, which indicates the onset of
33 a pandemic. WHO reported almost 30,000 confirmed cases of H1N1 and 145 deaths world wide as of
34 June 12, 2009.⁽⁹⁾ Over 13,000 cases and 27 deaths were reported in the United States.⁽⁹⁾ While this
35 outbreak did not have the severity of earlier pandemics, it is sufficiently similar to previous pandemics to
36 merit concern. It is not certain that the current H1N1 strain can mutate into a more virulent strain, but
37 healthcare workers are taking the possibility very seriously.

38 The modes for human-to-human transmission of influenza are actively debated⁽¹⁰⁻¹⁵⁾, but there are data
39 that support aerosol transmission.^(10,14) This information has led the Occupational Safety and Health
40 Organization (OSHA) and the Centers for Disease Control (CDC) to recommend that workers wear a
41 properly-fitted NIOSH-approved FFR during a pandemic influenza outbreak.^(16,17) To supply the general
42 public with protection and help mitigate the 2009 H1N1 epidemic, the FDA issued an Emergency Use
43 Authorization (EUA) that approved release of FFRs from the Strategic National Stockpile (SNS).⁽¹⁸⁾ The
44 Centers for Disease Control (CDC) estimates that during a pandemic lasting 42 days, over 90 million
45 FFRs will be required for healthcare workers only.⁽¹⁹⁾ These projections indicate that a shortage of FFRs

46 is likely to occur, which would leave healthcare workers exposed and might add to the severity of the
47 pandemic.

48 A possible solution for alleviating an FFR shortage is to decontaminate and reuse the FFRs.⁽¹⁹⁾ However,
49 data describing the effect decontamination technologies have on the performance of FFRs are sparse.
50 Filtration efficiency, pressure drop, fit, off-gassing of residual chemicals, and overall durability are key
51 questions that must be addressed. NIOSH has performed limited studies that indicate that some
52 technologies can be used to decontaminate FFRs without affecting performance.⁽²⁰⁾ However, other
53 technologies, such as autoclaving, render the FFRs unusable.⁽²⁰⁾ These tests were performed on a limited
54 number of FFR models, and more research is needed on a large number of FFRs to properly evaluate
55 decontamination technologies. The Air Force Research Laboratory (AFRL) is currently leading an effort
56 that examines the effects of several decontamination technologies on six commonly distributed models of
57 FFRs from the SNS (Table I). The six models of FFRs represent both common particulate FFRs and
58 those cleared by the FDA as medical devices. The focus of this report is chemical off-gassing following
59 decontamination; the other parameters will be the focus of future reports.

60 Many technologies could be used for decontaminating FFRs; however, they are too numerous to permit
61 an exhaustive evaluation. To narrow the scope, multiple characteristics of 10 diverse decontamination
62 technologies selected for applicability in three scenarios—major hospital, small clinic, first-responder
63 station—were evaluated: 1) Biocidal performance of the technology—historical data must demonstrate
64 biocidal efficacy on surfaces; 2) Cost—single-use FFRs will be decontaminated only in the event of an
65 FFR shortage caused by a pandemic influenza or similar disease, so it is impractical to allocate scarce
66 resources to purchase specialized equipment; 3) Availability—commercially available technologies were
67 the primary focus of this study; however, some emerging technologies were also considered. 4) FFR
68 compatibility—many technologies were eliminated that were known to degrade the performance of FFRs.
69 ⁽²⁰⁾ Data describing how FFRs respond to decontaminants are sparse, but care was taken to select
70 technologies that are not overly aggressive; and 5) End use—the decontamination technologies need to

71 provide useful solutions for end users ranging from very large hospitals to non-occupational users. Each
72 end user will have different tolerances for throughput and regeneration time of the FFRs.

73 The decontamination technologies selected for this study comprise gaseous, energetic, and liquid agents
74 (Table II). The large-scale/high-throughput technologies selected were vaporized hydrogen peroxide
75 (VHP) and ethylene oxide (EO) sterilizers. The achievable throughput using these technologies is
76 questionable, but since many hospitals already utilize these devices for low-heat sterilization they were a
77 logical choice for evaluation in this study. Both VHP and EO sterilizers are relatively expensive
78 technologies; however, organizations that own these devices have only a small burden of added
79 operational costs. The medium-throughput devices selected for the study were energetic devices:
80 conventional and microwave ovens routinely found in many organizations and homes, and ultraviolet
81 (UV) light: UV devices for surface sterilization are commercially available (Ultra Violet Products,
82 Upland, CA); however, distribution of these devices in hospitals and other clinical/first responder
83 organizations is unknown. If ultraviolet irradiation was found to be useful for decontaminating FFRs, the
84 technology might also have routine applications that could justify its acquisition by small or even large
85 organizations.

86 The small-scale decontaminants were all aqueous solutions—bleach (diluted to 0.6% hypochlorite) and
87 3% hydrogen peroxide are common disinfectants that can be found in most homes in America. Mixed-
88 oxidants and dimethyldioxirane (DMDO) were both developed as part of Department of Defense (DoD)
89 projects, and represent emerging technologies that are not widely distributed.^(21,22) They were included in
90 this study in case both bleach and peroxide performed unsatisfactorily. The technologies of primary
91 concern for off-gassing are the liquid and gaseous decontamination agents. Ultraviolet (UV) irradiation
92 (at both 254 nm and 302 nm) was also analyzed for possible by-products from UV-initiated radical
93 reactions. Since microwave and conventional ovens do not use chemicals, off-gassing analysis is not
94 relevant.

95 The analytical methods for off-gassing analysis (Table III) were selected based on the chemical properties
96 of each analyte. In most cases, head-space analysis using gas chromatography-mass spectrometry (GC-
97 MS) would be the preferred method, as this would detect chemical compounds that were off-gassed from
98 the FFR and likely to be respirable. EO was analyzed with this methodology using the guidance provided
99 in ISO 10993-7 international standard for the biological evaluation of medical devices.⁽²³⁾ However,
100 many of the disinfectants in this study are reactive and do not afford themselves to separation by GC. The
101 hydrogen peroxide agents (VHP and 3% liquid), hypochlorite, and DMDO fall into this category. Also,
102 whereas off-gassing is the primary concern, many of the decontaminants used for this study do not readily
103 off-gas. The active species for bleach is a hypochlorite salt that will not elute on a GC column but can
104 react with chloride to liberate chlorine as $\text{Cl}_2(\text{g})$. In addition, aqueous solutions containing hypochlorite
105 are very destructive to the stationary phase of the GC column. The mixed oxidants contain 6% sodium
106 bicarbonate, 5% sodium chloride, and 10% potassium peroxymonosulfate (Oxone[®]). The initial oxidative
107 capacity is provided by the Oxone[®]; however, it is also possible that Oxone[®] can react with NaCl to form
108 $\text{Na}^+(\text{aq})$ and $\text{ClO}^-(\text{aq})$. For the examples above, GC-MS would not be effective to quantify the chemicals.
109 To quantify the amount of trace chemicals left on the FFR by these technologies, iodometric back
110 titrations (IBTs) were carried out via the oxidation of sodium thiosulfate added to the samples. IBT is
111 commonly used for quantifying oxidative capacity⁽²⁴⁻²⁶⁾, and since all the chemical decontaminants used
112 in this study are oxidative in nature, the use of IBT was appropriate. Pentane extractions of
113 decontaminated FFRs were also conducted on specimens treated with any chemical disinfectant or with
114 UV light to ensure that additional hazards were not created during the decontamination. Pentane is an
115 organic solvent commonly used to extract volatile organic substances.

116

117 **Materials and Methods**

118 Liquid Decontaminants: Three FFRs of each model were submerged in liquid decontamination agents
119 (Table II) in a chemical fume hood for 30 minutes at room temperature. A volume of 200 mL of

120 decontaminant per FFR was used. After the 30-minute soak, the FFRs were removed from the solutions,
121 placed on trays, and allowed to off-gas for 18 hours in a chemical fume hood. Following the off-gassing
122 period, ten 14-mm diameter samples were punched from areas equally spaced on each respirator and
123 separately weighed in 20-mL glass scintillation vials. In addition, the straps, nose cushions, and metal
124 nosepieces were cut into small pieces and separately weighed in scintillation vials. Iodometric back
125 titrations were conducted as previously described.^(24, 25) Three additional 14-mm samples were removed
126 from each FFR and extracted with 10 mL of *n*-pentane for 3 hours. Extracts were analyzed using GC-MS
127 as follows: 2-mL aliquots were added to standard GC vials, and separated on a GC with a Programmed
128 Temperature Vaporization (PTV) injector in splitless mode. MS scans were taken from *m/z* 30.0–300.0 at
129 5 scans per second and a scan rate of 1807 (*m/z*)/s. Data were collected on a Thermo–Finnigan Trace GC
130 (Thermo Scientific, Waltham, MA) fitted with a 30-m x 0.32-mm x 0.25- μ m DB-5 column, using a Trace
131 DSQ MS with a Leap Technologies CTC Combi PAL[®] autosampler. The ion source temperature was
132 held at 225 °C and the detector gain was set to 1.0×10^5 .

133

134 Gaseous Decontaminants: An Amsco Eagle 3017 Ethylene Oxide Sterilizer[®] was used to expose triplicate
135 FFRs of each model to EO. The FFRs were packaged individually in sterilization pouches that contained
136 sterilization indicator strips. The sterilization cycle was 3 hours at 54 °C, followed by a 12-hour aeration
137 cycle at 54 °C. Following the off-gassing period, 14-mm diameter samples were punched from areas
138 equally spaced on each respirator and weighed in a Supelco 20-mL headspace vial. In addition, the
139 straps, nose cushions, and metal nosepieces were cut into smaller pieces and separately weighed in the
140 headspace vials. GC-MS analysis for EO used guidance from the ISO standard AAMI/ANSI/ISO 10993-
141 7.⁽²³⁾ Briefly, GC-MS analyses were carried out by headspace solid-phase micro extraction (HSSPME)
142 with a PTV injector used as a desorber. The HSSPME fibers were Supelco 65- μ m bonded phase
143 polymethylsiloxane–divinylbenzene. The MS operated in scan mode from *m/z* 20.0–120.0 with 5 scans
144 per second and a scan rate of 1807 (*m/z*)/s. For the HSSPME methods, an extraction time of 240 s was

145 used with a desorption time of 900 s. The GC temperature program began with a 40 °C isotherm for
146 4 min, followed by a ramp of 20 °C/min to 270 °C. The PTV injector was set to a base temperature of
147 250 °C, and the helium flow rate was 1.5 mL/min. Pentane extractions were also conducted as described
148 in the liquid decontaminants section.

149 A STERRAD[®] 100S system was used to expose triplicate FFRs of each model to VHP. The FFRs were
150 packaged individually in sterilization pouches that contained sterilization indicator strips. The
151 sterilization cycle was 55 minutes at 45–55 °C. Following the sterilization cycle, 14-mm diameter
152 samples were punched from areas equally spaced on each respirator and weighed in a 20-mL scintillation
153 vial. In addition, the straps, nose cushions, and metal nosepieces were cut into smaller pieces and
154 separately weighed in vials. Samples were analyzed by IBT and pentane extractions as described in the
155 liquid decontaminants section.

156 Energetic Decontaminants: Triplicate 38-mm diameter circles were cut from each FFR model. A multi-
157 wavelength, 8-watt lamp (Ultra Violet Products, Upland, CA), was used to expose triplicate samples of
158 each FFR model to UV light. Samples were placed 1 inch from the lamp source and were irradiated with
159 4.0 mW/cm² of UV-B (302 nm) and 3.4 mW/cm² UV-C (254 nm) for 1 hour each. A UV meter (Ultra
160 Violet Products, Upland, CA) was used to measure irradiance. After exposure, samples were weighed in
161 20-mL glass scintillation vials and extracted with pentane as described in the liquids decontaminants
162 section.

163

164 **Data Analysis**

165 Iodometric back titration (IBT): The data retrieved from this assay are initially reported in mmol of
166 oxidant per gram, which is converted to mg of oxidant by multiplying by the gram-molecular weight of
167 the decontaminant applied to the FFR. The mmol of oxidant recovered on untreated FFRs cannot be
168 converted into mg because the chemical identity of the native oxidant(s) is unknown. To correct the data
169 for the native amount of oxidant on the FFRs, the average amount of oxidant (mmol/gram) quantified

170 from the untreated FFRs was subtracted from the treated samples. The final formula for determining mg
171 of oxidant per FFR is described in Equation 1. The IBT assay can produce negative numbers, which have
172 no physical significance. In those cases, the negative numbers were viewed as below detection limit and
173 were excluded from the analysis. The value for the amount of oxidant present on each triplicate FFR was
174 imported in to Prism-5[®] software (GraphPad, La Jolla, California) and 95% confidence intervals were
175 calculated.

176 [Equation 1]: mg of oxidant per FFR

177

178 Equation (1) $\sum [(T - U) * W * G]_{pi}$

179 T = Treated mmol of oxidant per gram

180 U = Untreated mmol of oxidant per gram

181 W = Weight of FFR component in grams

182 G = Gram-molecular weight of the decontaminant

183 $pi = p1, p2, p3, p4$ = Different FFR parts (FFR respirator material, straps, nose cushion, metal nosepiece

184

185 Ethylene oxide HSSPME data analysis: The ISO standard for the biological evaluation of medical devices
186 provided much of the guidance for this analysis. ⁽²³⁾ The ISO method uses direct injections of headspace
187 gas quantified by external calibration using the ideal gas law. For this experiment, headspace analysis by
188 SPME fiber was acceptable since all recoveries of EO were presumed to be well below the OSHA
189 permissible exposure limit (PEL) of 1 ppm. ⁽²⁷⁾ FFRs treated with EO were analyzed by HSSPME GC-MS
190 as described above. Chromatographic analysis was carried out by manual recognition of Gaussian zones
191 at an approximate signal-to-noise ratio of 3:1 or greater. Signals recorded below this ratio were not
192 considered. A detection limit study for EO was used to determine a reasonable threshold value for the
193 technique. Aqueous standards of EO purchased from Accustandard (New Haven, CT) were serially
194 diluted to obtain concentrations of 10 ppm, 5 ppm, 1 ppm (PEL), 500 ppb, 50 ppb, 5 ppb and 0.5 ppb. EO
195 was found to elute at $t_R=5.60$ min with qualifying ions of m/z 44, 43, and 42. FFR samples were analyzed

196 over a window from 4.0–6.5 minutes to account for any variances in chromatography due to potential by-
197 products from EO alkylation. The detection limit for EO by HSSPME GC-MS was 500 ppb (half of the
198 PEL).

199
200 GC-MS *n*-pentane extraction data analysis: GC-MS analysis of the *n*-pentane extracts provided
201 chromatograms for each treated sample plus an untreated sample. Peaks present in the untreated sample
202 or the normal instrument background for pentane were subtracted from the treated samples. Peaks still
203 present were selected for investigation based on a visual comparison against the background signals of the
204 instrument and procedural materials. Peaks that exceeded a signal-to-noise ratio of 3:1 were analyzed
205 using Xcalibur[®] software (Thermo Scientific, Waltham, MA). The software provided peak identification
206 by comparing the acquired mass spectra to several spectral libraries contained within the software. The
207 first match provided by the software is not always the best match for the spectrum in question; however,
208 peaks were labeled as the first match when it was consistent with species present in the procedure.

209

210 **RESULTS**

211 Iodometric back titrations: The concentration of oxidant remaining on the FFRs varied depending on the
212 FFR model and decontamination technology (Table IV). All FFRs treated with 3% hydrogen peroxide
213 retained similar amounts of oxidant with the exception of the S3 FFR, which had no detectable oxidant.
214 The S1, S2, P1 and P2 models treated with VHP retained ~3X more oxidant than the other two models.
215 All FFR models treated with 10% bleach retained similar amounts of oxidant with the exception of the
216 S3, which held no detectable amount of oxidant. The P2 FFR retained more oxidant than the others, but
217 the data had large confidence intervals, which indicate the result is somewhat questionable. The same is
218 true for the mixed-oxidant-treated P2 and P3 FFRs, which retained large quantities of oxidant compared
219 to the other FFRs. The DMDO-treated FFRs stand out from the others because all FFR models retained
220 ~5X more oxidant than their counterparts treated with the other disinfectants.

221
222 GC-MS analysis of *n*-pentane extracts: Many unique peaks were identified in the *n*-pentane extracts (data
223 not shown); however, most of these were found in fewer than three FFRs, which suggests that they are
224 random events unrelated to the disinfection technologies. Table V provides data for the unique peaks that
225 were found in more than three of the 18 FFRs tested. For the chemical disinfection agents, a total of 11
226 unique peaks were identified, one a ubiquitous plasticizer and the remainder attributable to solvent
227 contamination or column background. UV irradiation produced the greatest number of unique peaks;
228 however, many of these appear to be constituents of the pentane solvent.

229
230 Ethylene oxide HSSPME results: EO was not directly detected in any of the respirators or respirator
231 components tested (Table VI). The total ion chromatograms were reviewed over a window from 4.0–6.5
232 minutes because time to elution of EO itself gradually decreased from ~5.6 to 5.2 minutes as removal of
233 contaminated sections at the front of the column decreased the working length of the GC column.
234 Furthermore, this large time window accommodated variations in chromatography such as retention time
235 shifts or peak fronting/tailing. Diacetone alcohol was found in 11 samples, 2-hydroxyethyl acetate
236 appeared in 15 samples, and cyclohexanone was identified in 2 samples. The 15 occurrences of 2-
237 hydroxyethyl acetate were all at or below the signal-to-noise ratio; however, the fact that they occurred so
238 frequently and were strap-specific warrants mention.

239
240 **Discussion**

241 The presence of oxidant on the FFRs following decontamination was not surprising. The critical
242 question, however, is whether enough decontaminant remained on the FFRs to cause health concerns to
243 the user. The data collected were compared to NIOSH's recommended exposure (REL = time-weighted
244 average [TWA] concentration for up to a 10-hour workday during a 40-hour workweek) and/or the Short
245 Term Exposure Limit (STEL = 15-minute TWA exposure that should not be exceeded at any time during
246 a workday).⁽²⁷⁾ Using the mean value for this comparison would be appropriate but a more-conservative

247 approach is to use the upper 95% Confidence Interval (CI). The REL for the nonvolatile hypochlorite salt
248 (bleach) is “not established” according to the Clorox[®] MSDS. NIOSH reports the REL for chlorine, the
249 off-gassing product from hypochlorite, as 1.47 mg/m³ and the PEL as 3 mg/m³. Under the assumption of
250 complete and instantaneous dissociation into Cl₂ (g), the upper 95% CI for two FFR models would exceed
251 the REL (Table IV). However, the equilibrium constant disfavors formation of chlorine so the
252 preponderance of the oxidant is expected to remain on the FFR as a hypochlorite salt and act only as a
253 potential skin irritant. Also, the REL is a TWA of exposure during a 10-hour period. If the slightly less-
254 improbable assumption is made that all of the oxidant is transformed into chlorine and inhaled at constant
255 concentration during one 10-hour period, the accumulated exposure would not exceed the REL. Because
256 the active agent in the mixed oxidants technology is hypochlorite, the previous discussion of bleach also
257 applies for this decontaminant.

258 The peroxide-based decontaminants (VHP and 3% hydrogen peroxide) left the lowest observable amount
259 of oxidant on the respirators. Only two models of respirators treated with VHP exceeded the REL of 1.4
260 mg/m³. As peroxide will be slow to off-gas, the previous discussion on hypochlorite is also relevant for
261 the peroxide-based decontaminants.

262 An analysis of the amount of oxidant retained by the various FFR parts reveals delineation between the
263 particulate and surgical FFRs (Figure 1). For the particulate FFRs a majority of the oxidant was
264 recovered from the filtering media for all five decontaminants that were evaluated. However, two of the
265 surgical FFRs (S2 and S3), retained very little oxidant on the filtering media. This is likely due to the
266 hydrophobic coating that is applied to the surgical FFRs to provide resistance to blood splatter and other
267 body fluids. As mentioned previously, the S3 FFR retained very little oxidant overall and this is partially
268 due to its simple design: it does not contain a nose cushion. The nose cushion in the S2, which is very
269 large compared to the nose cushions on the other FFRs, was responsible for retaining a majority of the
270 oxidant using the traditional decontamination methods. The data for the mixed oxidant decontaminant is
271 somewhat skewed due the overall low retention of oxidant. The DMDO is also a special case as it was

272 retained by the filtration media for all six FFRs. The outlier in the group is the S1 which is a surgical
273 FFR that retained oxidant on the filtration media. It did perform better than the particulate FFRs, but it is
274 unclear why the S2 and S3 FFRs retained no oxidant on the filtration media and the S1 retention varied
275 from 30% -50% for the traditional decontamination methods. GC-MS analysis of the *n*-pentane extracts
276 revealed many minor peaks (data not shown). Only 20 unique peaks were discovered that occurred on at
277 least three of the 18 FFRs evaluated for each decontamination method (Table V). Eleven of those peaks
278 were attributed to the chemical disinfectants and nine were discovered following UV disinfection. Many
279 of the peaks appear to be species related to the solvent (*n*-pentane) and are not due to the disinfectant.
280 Some products, such as tetramethylsilane and dodecamethylpentasiloxane, are known artifacts of column
281 bleed. Common laboratory contaminants such as butyl phthalate and bis (2-ethylhexyl) adipate used in
282 the synthesis of polymeric materials were also detected. While these were included in the results, it is
283 important to note that they probably are not derived from the decontamination technologies. Although
284 background subtraction was performed via the negative controls, some treated samples indicated the
285 presence of additional chemicals similar to those found within the controls. It was expected that these
286 peaks would have been discovered in the negative controls (untreated FFRs and pentane control), but
287 many of these peaks were at the instrument detection limit and may have been overlooked. The peaks
288 that are due to column bleed are inherently random, although they will always increase in concentration
289 as the oven temperature increases. Solvent-derived compounds that did not match the controls were also
290 discovered in some of the treated samples. As the study progressed, GC maintenance necessitated
291 trimming several inches off the front end of the capillary column. While we have tried to account for
292 shifts in retention time caused by this procedure, some of the peaks might not have been precisely tracked
293 through the entire course of the study.

294 Although the respirators were found to be entirely free of EO, several of the models and components
295 tested contained diacetone alcohol and 2-hydroxyethyl acetate. Diacetone alcohol is a Class II
296 combustible liquid with a REL of 50 ppm.⁽²⁷⁾ While it is uncertain that an adequate amount of this

297 compound was present to affect human health, further studies should be conducted to ascertain the
298 exposure threat before this technology is considered for disinfecting respirators. Because it is classified
299 as a possible carcinogen, no REL or PEL is listed for 2-hydroxyethyl acetate (acetic acid, 2-hydroxyethyl
300 ester).⁽²⁸⁾ This compound might have formed via EO alkylation of vinyl acetate, a common component
301 of rubber. Rubber straps were components of every FFR tested with the exception of S1 (straps
302 composed of an elastic material containing rubber) and P2 (straps composed of a thermoplastic elastomer
303 which contains rubber). As with any unfamiliar compound, caution is warranted until the exact nature of
304 the substance is determined. Although the concentration recovered was minute, avoiding human
305 exposure to this compound would be prudent when there are clearly safer alternatives.

306

307 **Summary and Limitations of the Study**

308 The data from this study demonstrate readily available decontamination technologies that do not leave
309 significant quantities of toxic residues on the FFRs. UV irradiation and the peroxide-based technologies
310 (VHP and 3% hydrogen peroxide) provided favorable results for all FFR models tested. Diluted
311 household bleach (0.6% hypochlorite) also produced acceptable results; nevertheless, it should be noted
312 that all FFRs treated with bleach retained a bleach odor following the off-gassing period. At a minimum,
313 the odor is unpleasant and may cause adverse health effects in users with certain asthmatic conditions.
314 Also, bleach rusted the metal parts on the FFRs (staples, nosepieces, etc.) and discolored others. For
315 these reasons, bleach is not recommended for decontaminating FFRs. The two emerging technologies,
316 DMDO and mixed oxidants demonstrated similar problems. DMDO retained the greatest amount of
317 oxidant, but no PEL is available for DMDO, thus human safety concerns cannot be evaluated.

318 Both gaseous sterilizers (EO and VHP) left very little of the active species on the FFRs following
319 decontamination and off-gassing. However, both techniques have undesirable traits that limit their use for
320 decontaminating FFRs: EO treatment of FFRs produced 2-hydroxyethyl acetate: a hazardous chemical

321 by-product, possibly formed by a reaction of EO with rubber parts of the respirator. Further studies are
322 needed to clarify these observations. Additionally, EO requires a long off-gassing period that will limit
323 throughput. Throughput is also a problem for the VHP technology—our experience during testing with
324 the VHP sterilizer was a sterilization cycle abortion if more than six FFRs were loaded in the chamber
325 during the one-hour sterilization cycle. It is know that cellulosic material will absorb peroxide ⁽²⁹⁾, but the
326 masks do not appear to contain cellulose. The main component of the FFRs appear to be polyester (40 -
327 70% by weight, mmm.com). We could not find any data to support that polyester absorbs peroxide. It is
328 unclear why the FFRs would have resulted in abortion of the VHP cycle.

329 This study is an initial look at the potential toxicity of FFRs following decontamination. The authors do
330 not endorse any method for decontaminating FFRs. More data are needed to measure the effect of
331 candidate decontaminants on filtration efficiency, fit, and the ability of each method to decontaminate the
332 influenza virus *in situ*. These studies are in progress and will be reported in the near future. Additional
333 work is also needed on other models of FFRs. This study focused on six models of FFRs, but hundreds
334 exist and each must be tested before conclusions can be made about compatibility with specific
335 decontamination technologies.

336

337 **References**

- 338 **1. Balazy, A., M. Toivola, A. Adhikari, S. K. Sivasubramani, T. Reponen, and S. A.**
339 **Grinshpun.** 2006. Do N95 respirators provide 95% protection level against airborne viruses,
340 and how adequate are surgical masks? *AJIC state of the science report* **34**:21–57.
- 341 **2. Chen, S.-K., D. Vesley, L. M. Brosseau, and J. A. Vincent.** 1994. Evaluation of Single-use
342 Masks and Respirators of Protection of Health Care Workers Against Mycobacterial
343 Aerosols. *Am. J. Infect. Control* **22**:65–74.
- 344 **3. Eshbaugh, J. P., P. D. Gardner, A. W. Richardson, and K. C. Hofacre.** 2009. N95 and
345 P100 respirator filter efficiency under high constant and cyclic flow. *J Occup Environ Hyg*
346 **6**:52–61.
- 347 **4. Heimbuch, B.K., and J.D. Wander.** 2006. *Bioaerosol challenges to antimicrobial surface*
348 *treatments: enhanced efficacy against MS2 coli phage of air filter media coated with*
349 *polystyrene-4-methyltrimethylammonium triiodide*. AFRL-ML-TY-2006-4527, Air Force
350 Research Laboratory, Tyndall Air Force Base, Fl. Defense Technical Information Center
351 (DTIC).
- 352 **5. McCullough, N. v., L. M. Brosseau, and D. Vesley.** 1997. Collection of Three Bacterial
353 Aerosols by Respirator and Surgical Mask Filters under Varying Conditions of Flow and
354 Relative Humidity. *Ann. Occup. Hyg.* **41**:677-690.
- 355 **6. Qian, Y., K. Willeke, S. A. Grinshpun, J. Donnelly, and C. C. Coffey.** 1998. Performance
356 of N95 Respirators: Filtration Efficiency for Airborne Microbial *and Inert Particles*. *Am.*
357 *Ind. Hyg. Assoc. J.* **59**:128–132
- 358 **7. Dawood, F. S., S. Jain, L. Finelli, and et al.** 2009. Emergence of a Novel Swine-Origin
359 Influenza A (H1N1) Virus in Humans. *New England Journal of Medicine* **360**:2605-2615.

- 360 **8. Naffakh, N., and S. v. d. Werf.** 2009. April 2009: An Outbreak of Swine-Origin Influenza
361 A (H1N1) Virus With Evidence for Human-to-Human Transmission. *Microb Infect*, in press
362 (doi:10.1016/j.micinf.2009.05.002).
- 363 **9. Influenza A (H1N1)** - update 45, Geneva: World Health Organization, June 8, 2009 at
364 http://www.who.int/csr/don/2009_06_08/en/index.html.
- 365 **10. Blachere, F. M., W. G. Lindsley, T. A. Pearce, S. E. Anderson, M. Fisher, R. Khakoo, B.**
366 **J. Meade, O. Lander, S. Davis, R. E. Thewlis, I. Celik, B. T. Chen, and D. H. Beezhold.**
367 2009. Measurement of Airborne Influenza Virus in a Hospital Emergency Department. *Clin.*
368 *Infectious Diseases* **48**:438–40.
- 369 **11. Bridges, C. B., M. J. Kuehnert, and C. B. Hall.** 2003. Transmission of influenza:
370 Implications for control in health care settings. *Clinical Infectious Diseases* **37 (8)**:—1094-
371 101.
- 372 **12. Goldman, D. A.** 2000. Transmission of viral respiratory infections in the home. *Pediatric*
373 *Infectious Disease Journal* **19**:S97–S102.
- 374 **13. Salgado, C. D., B. M. Farr, H. K.K., and F. G. Hayden.** 2002. Influenza in acute hospital
375 setting. *Lancet Infectious Disease* **2**:145–155
- 376 **14. Tellier, R.** 2006. Review of Aerosol Transmission of Influenza A Virus. *Emerging Infectious*
377 *Diseases* **12**:1657–1662.
- 378 **15. Weber, T. P., and N. I. Stilianakis.** 2008. Inactivation of influenza A viruses in the
379 environment and modes of transmission: A critical review. *J. Infection* **57**:361–373.
- 380 **16. Centers for Disease Control and Prevention (CDC):** *Guideline for Isolation Precautions:*
381 *Preventing Transmission of Infectious Agents in Healthcare Settings 2007.* J.D. Siegel and

382 the Healthcare Infection Control Practices Advisory Committee (2007),
383 http://www.cdc.gov/ncidod/dhqp/gl_isolation.html (accessed October 20, 2008).

384 **17. Occupational Safety and Health Administration (OSHA): *Pandemic Influenza***
385 *Preparedness and Response Guidance for Healthcare Workers and Healthcare Employers.*
386 Pub. No. OSHA 3328-05 (2007).

387 **18. Centers for Disease Control and Prevention (CDC): FDA Issuance Letter for N95**
388 *Respirators, 2009*, J.M. Sharfstein, Principal Deputy Commissioner, Acting Director of
389 Food and Drugs. <http://www.cdc.gov/h1n1flu/eua/pdf/N95-amendment-letters.pdf>

390 **19. Bailar, J.C., Brosseau, L.M., Cohen, H.J., et al.** 2006. *Reusability of Facemasks during an*
391 *Influenza Pandemic.* Washington D.C.: Institute of Medicine, National Academies Press.

392 **20. Viscusi, D.J., King, W.P., and R.E. Shaffer.** 2007. Effect of Decontamination on the
393 Filtration Efficiency of Two Filtering Facepiece Respirator Models. *J. Int. Soc. Resp. Prot.*
394 24:93–107.

395 **21. Delcomyn, C. A., K. E. Bushway, and M. V. Henley.** 2006. Inactivation of Biological
396 Agents Using Neural Oxone–Chloride Solutions. *Environ. Sci. Technol.* 40:2759–2764.

397 **22. Wallace, W. H., K. E. Bushway, S. D. Miller, C. A. Delcomyn, J. J. Renard, and M. V.**
398 **Henley.** 2005. Use of in situ-generated Dimethyldioxirane for inactivation of biological
399 agents. *Environ. Sci. Technol.*, 39 (16): 6288 - 6292

400 **23. International Standard ISO 10993-7, *Biological evaluation of medical devices—Part 7:***
401 *Ethylene oxide sterilization residuals*, 1995

402 **24. Qian, L. G. Sun.** 2003. Durable and Regenerable Antimicrobial Textiles: Synthesis and
403 Applications of 3-methylol-2,2,5,5-tetramethyl-imidazolidin-4-one (MTMIO) *J. Appl.*
404 *Polymer Sci.*, 89: 2418–2425

- 405 **25. Y. Sun and G. Sun.** 2003. Novel Refreshable *N*-halamine Polymeric Biocides: Grafting
406 Hydantoin-Containing Monomers onto High Performance Fibers as a Continuous Process. *J.*
407 *Appl. Polymer Sci.*, 88: 1032–1039
- 408 **26. B. Salter, J. Owens, R. Hayn, R. McDonald, E. Shannon.** 2009. *N*-chloramide modified
409 Nomex as a regenerable self-decontaminating material for protection against chemical
410 warfare agents. *J. mater. Sci.* 44(8): 2069-2078
- 411 **27. National Institute for Occupational Safety and Health (NIOSH):** *Pocket Guide to*
412 *Chemical Hazards.* DHHS (NIOSH) Pub. No. 2005-149. Washington, D.C. Government
413 Printing Office. (2007)
- 414 **28. TCI America,** online catalog, *MSDS for 2-hydroxyethyl acetate:*
415 <http://www.tciamerica.com/catalog/A1059.html>
- 416 **29. Jones, R., Drake, J., and Eagleson, D.** 1993. Using hydrogen peroxide vapor to
417 decontaminate biological safety cabinets. *Acumen* 1(1): 1–3
418

419

420 **TABLE I.** Filtering Facepiece Respirators Selected for Decontamination Study

Number	Class	Shape
S1	NIOSH and FDA approved N95 Surgical FFR	Cup-shaped
S2		Flat-fold
S3		Duck-bill
P1	NIOSH approved N95 Particulate FFR	Cup-shaped
P2		Cup-shaped
P3		Cup-shaped

421

422

423 **TABLE II.** Disinfection technologies

Large Scale (gaseous)	Ethylene oxide
	Vaporized hydrogen peroxide
Medium Scale (energetic)	Moist heat (65 °C, 85% RH)
	Desiccation (<10% RH)
	Microwave/steam
	Ultraviolet light (254 and 302 nm, $\sim 2.7 \times 10^5$ J/M ²)
Small Scale (liquid)	Hydrogen peroxide (3%)
	Sodium hypochlorite (0.6%)
	Mixed oxidants (10% oxone, 6%, sodium chloride, 5% sodium bicarbonate)
	Dimethyl dioxirane (10% oxone, 10% acetone, 5% sodium bicarbonate)

424

425

426 **TABLE III.** Analytical Methods for Quantifying Decontamination Agents on FFRs

Decontamination Agent	Concentration	Analysis Method
Untreated	N/A	Iodometric back-titration, GC-MS HSSPME Pentane extraction
Hydrogen peroxide	3%	Iodometric back-titration, Pentane extraction
Sodium hypochlorite	0.6%	Iodometric back-titration, Pentane extraction
Mixed oxidants	10% oxone, 6%, sodium chloride, 5% sodium bicarbonate	Iodometric back-titration, Pentane extraction
Dimethyl dioxirane	10% oxone, 10% acetone, 5% sodium bicarbonate	Iodometric back-titration, Pentane extraction
Ethylene oxide	Amsco Eagle 3017	GC-MS HSSPME, Pentane extractions
Vaporized hydrogen peroxide	Sterrad 100S System	Iodometric back-titration, Pentane extraction
Ultraviolet light (254 & 302 nm)	$\sim 2.7 \times 10^5$ J/M ²	Pentane extraction

427

428 **TABLE IV.** Oxidant (mg) Remaining on FFRs Following Decontamination and 18-Hours Off-
 429 Gassing

3% Hydrogen Peroxide						
Respirators	S1	S2	S3	S4	S5	S6
Average	0.59	0.36	ND	0.43	0.53	0.70
Lower 95% CI	0.14	0.28	----	0.12	0.20	0.38
Upper 95% CI	1.04	0.45	----	0.74	0.87	1.02
Vaporized Hydrogen Peroxide						
Respirators	S1	S2	S3	S4	S5	S6
Average	1.23	0.43	0.36	1.09	0.81	0.35
Lower 95% CI	0.68	0.29	-0.11	0.64	0.29	0.04
Upper 95% CI	1.77	0.57	0.83	1.53	1.34	0.66
10% Bleach						
Respirators	S1	S2	S3	S4	S5	S6
Average	0.37	0.70	ND	0.32	1.66	0.45
Lower 95% CI	0.00	0.29	----	-0.31	-2.03	-0.64
Upper 95% CI	0.73	1.11	----	0.95	5.34	1.54
Mixed Oxidants						
Respirators	S1	S2	S3	S4	S5	S6
Average	0.14	0.08	ND	0.25	1.72	8.10
Lower 95% CI	-0.05	-0.08	----	-1.53	-1.38	3.06
Upper 95% CI	0.32	0.24	----	2.03	4.82	13.14
DMDO						
Respirators	S1	S2	S3	S4	S5	S6
Average	7.38	7.72	4.53	5.53	7.19	5.14
Lower 95% CI	6.87	-0.09	2.52	5.11	6.50	3.95
Upper 95% CI	7.89	15.53	6.53	5.94	7.87	6.33
ND - none detected						

430

431

432

433 **TABLE V.** GC-MS Unique* Peaks of Pentane Extracted FFR Found in Greater than 3/18 of the
 434 FFRs tested

Decontaminant	Unique Peaks Retention Time (min)	Peak Occurrence Among All FFR Models	Peak ID*
Hydrogen peroxide (3%)	3.98	14 / 18	Hexane
	13.13	4 / 18	Siloxane derivative
	14.63	4 / 18	Siloxane derivative
Vaporized hydrogen peroxide	3.98	14 / 18	Hexane
0.6 % Hypochlorite	4.46	5 / 18	Aliphatic hydrocarbon
Mixed oxidants	3.97	7 / 18	Hexane
	3.98	10 / 18	Hexane
Dimethyldioxirane	7.28	12 / 18	Siloxane derivative
	8.68	13 / 18	Siloxane derivative
	13.75	6 / 18	Siloxane derivative
Ethylene oxide	11.42	5 / 18	Aliphatic hydrocarbon
Ultraviolet (254 and 302 nm)	3.71	4 / 18	Aliphatic hydrocarbon
	3.72	8 / 18	Aliphatic hydrocarbon
	4.67	4 / 18	Aliphatic hydrocarbon
	5.7	15 / 18	Aliphatic hydrocarbon
	7.06	4 / 18	Aliphatic hydrocarbon
	7.07	10 / 18	Aliphatic hydrocarbon
	11.09	5 / 18	Aliphatic hydrocarbon
	13.22	5 / 18	Butyl phthalate
	13.23	11 / 18	Butyl phthalate

435 * Most likely match by Xcaliber™ software

436


437 **TABLE VI.** Unique Peaks from HSSPME Analysis of Ethylene Oxide Treated FFRs Present on
 438 Greater than 3/18 FFRs

Unique Peaks Retention Time (min)	Peak Occurrence Among All FFR Models	Peak ID*
5.3-5.33	11 / 18	Diacetone alcohol
5.49	15 / 18**	2-Hydroxyethyl acetate
* Most likely match by Xcaliber™ software		
** Only detected on straps		

439

440

441



442

443 **FIGURE 1.** Percent Oxidant Recovered From FFR Components.